PHAT (Phathom Pharmaceuticals) LT-Debt-to-Total-Asset: 0.54 (As of Mar. 2026)


PHAT Phathom Pharmaceuticals Inc PHAT
23 GF Score
Price $10.87
! 3 Warning Signs
View Full Analysis

What is Phathom Pharmaceuticals LT-Debt-to-Total-Asset?

Phathom Pharmaceuticals PHAT +1.40% 23 LT-Debt-to-Total-Asset is 0.54 as of Mar. 2026. GuruFocus rates PHAT with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Phathom Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.54.

Phathom Pharmaceuticals's long-term debt to total assets ratio declined from Mar. 2025 (0.69) to Mar. 2026 (0.54). It may suggest that Phathom Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Phathom Pharmaceuticals  (NAS:PHAT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Phathom Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Phathom Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Phathom Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phathom Pharmaceuticals LT-Debt-to-Total-Asset Chart

Phathom Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.48 0.59 0.33 0.53 0.82

Phathom Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.82 0.87 0.82 0.54
PHAT
23GF Score
Phathom Pharmaceuticals Inc PHAT
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Phathom Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Phathom Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=211.152/259.149
=0.81

Phathom Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=165.636/305.12
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.54 mean?
Phathom Pharmaceuticals (PHAT) has a LT-Debt-to-Total-Asset of 0.54 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Phathom Pharmaceuticals and its competitors.
Is Phathom Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Phathom Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.54. Overall, Phathom Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Phathom Pharmaceuticals' LT-Debt-to-Total-Asset compare to GERN and ODTX?
Phathom Pharmaceuticals' LT-Debt-to-Total-Asset of 0.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Phathom Pharmaceuticals and its competitors. Phathom Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phathom Pharmaceuticals stock overvalued right now?
Phathom Pharmaceuticals (PHAT) has a current LT-Debt-to-Total-Asset of 0.54. The current LT-Debt-to-Total-Asset is 0.54. Phathom Pharmaceuticals' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Phathom Pharmaceuticals (PHAT), the current LT-Debt-to-Total-Asset is 0.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Phathom Pharmaceuticals Business Description

Address 100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
23GF Score

Get the complete analysis for PHAT

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.87
Price